SRS Capital Advisors Inc. Has $2.48 Million Position in Johnson & Johnson (NYSE:JNJ)

SRS Capital Advisors Inc. grew its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 10.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,161 shares of the company's stock after purchasing an additional 1,682 shares during the quarter. SRS Capital Advisors Inc.'s holdings in Johnson & Johnson were worth $2,482,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. IFS Advisors LLC raised its stake in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after purchasing an additional 100 shares during the period. RPg Family Wealth Advisory LLC acquired a new position in shares of Johnson & Johnson in the third quarter worth $35,000. Bay Harbor Wealth Management LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter worth $32,000. Activest Wealth Management acquired a new position in shares of Johnson & Johnson in the third quarter worth $40,000. Finally, Fiduciary Advisors Inc. acquired a new position in shares of Johnson & Johnson in the fourth quarter worth $43,000. 69.55% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on JNJ. Bank of America increased their target price on shares of Johnson & Johnson from $159.00 to $171.00 and gave the stock a "neutral" rating in a research report on Wednesday. Raymond James lowered their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating on the stock in a research report on Thursday, January 23rd. Citigroup lowered their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research report on Wednesday, December 11th. Guggenheim increased their target price on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a "neutral" rating in a research report on Monday, February 3rd. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $171.33.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ traded down $0.20 during mid-day trading on Wednesday, hitting $165.22. The company had a trading volume of 8,744,672 shares, compared to its average volume of 7,006,371. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The business's 50-day simple moving average is $152.11 and its 200-day simple moving average is $156.19. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The firm has a market cap of $397.79 billion, a P/E ratio of 24.85, a PEG ratio of 2.56 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion during the quarter, compared to analysts' expectations of $22.44 billion. During the same quarter last year, the company earned $2.29 earnings per share. The firm's revenue was up 5.3% on a year-over-year basis. As a group, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.00%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson's payout ratio is presently 74.59%.

Insiders Place Their Bets

In other news, Director Mark A. Weinberger acquired 1,000 shares of the company's stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.